ImmunoGen’s Merger with AbbVie Awaits Shareholder Approval
Company Announcements

ImmunoGen’s Merger with AbbVie Awaits Shareholder Approval

Immunogen (IMGN) has released an update.

ImmunoGen, Inc. entered into a Merger Agreement with AbbVie and its subsidiaries on November 30, 2023, with ImmunoGen set to survive as a subsidiary post-merger. The German Federal Cartel Office approved the merger unconditionally on January 29, 2024. Completion of the merger is subject to further conditions, including approval by ImmunoGen’s shareholders and compliance with the Hart-Scott-Rodino Antitrust Improvements Act. ImmunoGen has filed a definitive proxy statement with the SEC and is soliciting votes from shareholders regarding the merger.

For further insights into IMGN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyTwo option delistings on February 21st
TipRanks Auto-Generated NewsdeskImmunoGen Finalizes Merger, Amends Operations, and Delists Shares
TheFlyAbbVie completes the acquisition of ImmunoGen
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App